Brought to you by 
GSK improves position in emerging markets with Egyptian buy
17 Oct 2008
Executive Summary
Bristol-Myers Squibb has sold its mature products business in Egypt to GlaxoSmithKline for $210mm. The acquisition gives GSK a leading position with a 9% share of this emerging pharmaceutical market, which is worth approximately $2.1bn.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Divestiture/Spin-Out
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com